New Treatment for Cat Diseases Commercialized

The partnership will make available a new treatment for cats infected with leukemia and immunodeficiency viruses.

Posted: December 21 2007 2 a.m. EDT

Printer Friendly

New Treatment for Cat Diseases Commercialized
Cats with Feline Leukemia Virus and Feline Immunodeficiency Virus will soon have a new treatment option.
Through a recent partnership, T-Cyte Therapeutics Inc. will manufacture Lymphocyte T-Cell Immunomodulator (LTCI) while Imulan BioTherapeutics LLC will focus on technical services, clinical trials and product distribution.

LTCI is conditionally approved as a treatment aid for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV) infections.

“We are delighted to partner with T-Cyte and make available the only approved treatment in the United States for cats infected with leukemia and immunodeficiency viruses,” said Craig Woods, DVM, chief executive officer of Imulan. “This technology represents an important advancement in immune based treatment strategies for animal health diseases.”

Imulan is based in Scottsdale, Ariz. T-Cyte, a subsidiary of S-Cell Biosciences, is based in San Diego.

Printer Friendly

 Give us your opinion on
New Treatment for Cat Diseases Commercialized

Submit a Comment   Join Club
Earn 1,000 points! What's this?
Reader Comments

Ellen    Attleboro, MA

12/22/2007 12:38:25 AM

Wonderful news!

Cheryl    Conway, MO

12/21/2007 7:32:42 PM

Its great to know that there may be a cure for the feline virus. Who knows what they may be able to figure out from all of this.

ML    Williamsport, PA

12/21/2007 7:24:28 AM

Oh this is more than wonderful! A great breakthrough for the furbabies who have this disease. But even with this new technology please consider keeping your cats indoors always so they do not run the risk of being exposed to the disease.

Lisa    Hanover, PA

12/21/2007 7:20:19 AM

Thats great that they came out with this!! It is hard to lose a cat from this.

View Current Comments


Top Products

ADS BY GOOGLE